Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 school-based teletherapy for students with 60+ district partnerships; $25M total ($13M USV/Lux/Lightspeed Series B Aug 2023) competing with Hazel Health and Brightline for school district mental health access.
Daybreak Health is a San Francisco-based school-based teletherapy platform — backed by Y Combinator (W20) with $25 million in total funding including a $13 million Series B in August 2023 led by Union Square Ventures with Lux Capital, Lightspeed Venture Partners, Maven Ventures, and Y Combinator, following a $10 million Series A in 2022 and $1.8 million seed in 2021 — providing school districts with high-quality, affordable, and culturally competent virtual mental health therapy for students, partnering with 60+ school districts since 2019 to address the student mental health crisis through personalized counseling delivered by licensed therapists through telehealth. Founded in 2019, Daybreak positions as the leading school-based teletherapy provider focused on making mental health support accessible to all students regardless of socioeconomic status.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.